Table 4, Key Characteristics of Ustekinumab, Vedolizumab, Infliximab, and Adalimumab - Ustekinumab (Stelara)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Ustekinumab (Stelara) [Internet].

Contents

Table 4Key Characteristics of Ustekinumab, Vedolizumab, Infliximab, and Adalimumab

	Ustekinumab	Vedolizumab	Infliximab	Adalimumab
Mechanism	IL-12 and IL-23 inhibitor	Integrin inhibitor	TNF alpha antagonist
Indications^a	Adult CD Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, loss of response to, or intolerance to either conventional therapy (CS or immunomodulators) or one or more TNF antagonist, or who were CS dependent	Adult CD Adult patients with moderately to severely active CD who have had an inadequate response with, loss of response to, or intolerance to immunomodulators or a TNF antagonist; or who have had an inadequate response to, intolerance to, or demonstrated dependence on CS	Adult CD Reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing and reduction of CS use in adults with moderately to severely active CD who have had an inadequate response with a CS and/or aminosalicylate Pediatric CD Reduction of signs and symptoms and induction and maintenance of clinical remission in pediatrics with moderately to severely active CD who have had an inadequate response with conventional therapy Fistulizing CD Adults with fistulizing CD who have not responded despite conventional treatment	Adult CD Reduction of signs and symptoms and induction and maintenance of clinical remission in adults with moderately to severely active CD who have had an inadequate response with conventional therapy Reduction of signs and symptoms and induction of clinical remission in adults with moderately to severely active CD who have loss of response to or intolerance to infliximab Pediatric CD Reduction of signs and symptoms and induction and maintenance of clinical remission in severely active CD and/or who have had an inadequate response with or intolerance to conventional therapy and/or a TNF antagonist
Administration	IV (induction) and SC (maintenance)	IV		SC
Recommended Dose	Induction: tiered weight-based dose approximating 6 mg/kg IV at week 0 Maintenance: 90 mg SC at week 8 and q.8.w. thereafter Alternative maintenance: 90 mg SC at week 12 and q.12.w. thereafter; may switch to q.8.w. for inadequate response	Adults (moderate-to-severe CD) Induction: 300 mg at weeks 0, 2, and 6 Maintenance: 300 mg q.8.w. starting at week 6	Adults (moderate-to-severe CD) Induction: 5 mg/kg at weeks 0, 2, and 6 Maintenance: 5 mg/kg q.8.w.; 10 mg/kg for incomplete responders Adults (fistulizing CD) Induction: 5 mg/kg at weeks 0, 2, and 6 Maintenance: 5 mg/kg q.8.w. or 10 mg/kg q.8.w. for those with relapse following an initial response Pediatrics (moderate-to-severe CD) Induction: 5 mg/kg at weeks 0, 2, and 6 Maintenance: 5 mg/kg q.8.w.	Adult CD Induction: 160 mg at week 0, 80 mg at week 2 Maintenance: 40 mg q.2.w. beginning at week 4; dose escalation for patients with a disease flare or nonresponse Pediatrics CD Induction: 160 mg at week 0, 80 mg at week 2 Maintenance: 20 mg q.2.w. beginning at week 4, 40 mg q.2.w. for patients with a disease flare or nonresponse
Serious Side Effects/Safety Issues	Infections and reactivation of latent infections Administration site reactions Malignancy	Serious infections Infusion and serious allergic reactions	Serious infections Malignancy Infusion and serious allergic reactions	Serious infections Malignancies, particularly lymphoma Administration-site reactions

: CD = Crohn’s disease; CS = corticosteroids; IL = interleukin; IV = intravenous; SC = subcutaneous; TNF = tumour necrosis factor; q.2.w. = every two weeks; q.8.w. = every eight weeks; q.12.w. = every 12 weeks.
a: Health Canada indication.
: Source: Ustekinumab product monograph,⁴ vedolizumab product monograph,²⁴ infliximab product monograph,^18,19 and adalimumab product monograph.²⁰

From: 1, INTRODUCTION

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

Cite this Page
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Table 4, Key Characteristics of Ustekinumab, Vedolizumab, Infliximab, and Adalimumab.

Other titles in this collection

CADTH Common Drug Reviews

Recent Activity

Clear Turn Off Turn On

Table 4, Key Characteristics of Ustekinumab, Vedolizumab, Infliximab, and Adalim...
Table 4, Key Characteristics of Ustekinumab, Vedolizumab, Infliximab, and Adalimumab - Ustekinumab (Stelara)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on